1 Start 2 Complete
*
*
*
*
*
*
*
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Presentation was at the appropriate level
Presentation was based on evidence
Handout materials were organized and useful
Speaker was excellent
Speaker was an effective teacher
Speaker engaged the audience in learning
Learning assessment questions were appropriate
Content will have a positive impact on how I practice
The presentation was balanced and unbiased
*
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Recognize patients with chronic kidney disease (CKD) and their severity of disease.
Describe current issues with access to care and inequities in CKD.
Identify new medications for treating albuminuria and anemia of CKD.
Describe the new kidney payment models and how pharmacists can participate.
*
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Presentation was at the appropriate level
Presentation was based on evidence
Handout materials were organized and useful
Speaker was excellent
Speaker was an effective teacher
Speaker engaged the audience in learning
Learning assessment questions were appropriate
Content will have a positive impact on how I practice
The presentation was balanced and unbiased
*
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Describe the clinical practice impact of updates to the diabetes guidelines.
Differentiate glucagon-like peptide-1 (GLP-1) receptor agonists for management of type 2 diabetes.
Summarize new glucagon options for management of hypoglycemia.
Given a case, select an evidence-based patient centered pharmacotherapeutic plan for an older adult with type 2 diabetes.
*
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Presentation was at the appropriate level
Presentation was based on evidence
Handout materials were organized and useful
Speaker was excellent
Speaker was an effective teacher
Speaker engaged the audience in learning
Learning assessment questions were appropriate
Content will have a positive impact on how I practice
The presentation was balanced and unbiased
*
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Evaluate the current evidence for use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in the treatment of heart failure and/or chronic kidney disease.
Discuss pertinent guideline recommendations regarding the use of SGLT2i in patients with heart failure and/or chronic kidney disease.
Identify patients with heart failure and/or chronic kidney disease who would be appropriate candidates for treatment with SGLT2i therapy.
*
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Presentation was at the appropriate level
Presentation was based on evidence
Handout materials were organized and useful
Speaker was excellent
Speaker was an effective teacher
Speaker engaged the audience in learning
Learning assessment questions were appropriate
Content will have a positive impact on how I practice
The presentation was balanced and unbiased
*
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Discuss the pathophysiology and diagnosis of pulmonary arterial hypertension.
Based pathophysiology, quantify treatment modalities for the management of pulmonary arterial hypertension.
Summarize guideline recommendations for the treatment of pulmonary hypertension.
Identify patient education resources for patients diagnosed with pulmonary arterial hypertension.
*
*
*